Waled Bahaj, MD retweeted
On June 23, 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic EGFR-mutated non-small cell #LungCancer ( #NSCLC ) who have previously received EGFR-directed therapy and platinum-based chemotherapy.
fda.gov/drugs/resources-info…
This approval was based on efficacy data from the TROPION-Lung05 and TROPION-Lung01 trials, which showed an overall response rate of 45% and a median duration of response of 6.5 months in a subgroup of 114 patients.
@ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @JackWestMD @bmassutis @Tony_Calles @s_couraud @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @BairdAM
@jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo
@MartinReck2 @Latinamd @bmassutis
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua
Waled Bahaj, MD retweeted
🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert
Waled Bahaj, MD retweeted
Day 1 #ASCO25 highlights:
1. Review on recent approvals
2. #BREAKWATER (update): BRAF+ mCRC
3. #CM8HW (update): MSI-H mCRC
4. #DYNAMIC: ctDNA in colon ca
5. #CAIRO6: periOP Rx in peritoneal mets
#OncTwitter @ASCO
1/6
Waled Bahaj, MD retweeted
The most impressive myeloma abstract at #ASCO25
Outstanding longterm efficacy with cilta-cel CAR-T.
5 year survival rate 50%
5 year PFS rate of 33%
Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri @bhemato @BerdejaJesus
meetings.asco.org/abstracts-…
Waled Bahaj, MD retweeted
Magrolimab once showed promise in TP53-mutated AML, but recent data didn’t meet the mark, and development has been halted. A tough reminder of the challenges in translating early hope into clinical success. #AML onlinelibrary.wiley.com/doi/…
Waled Bahaj, MD retweeted
First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies @JournalCancer
doi.org/10.1002/cncr.35840
Waled Bahaj, MD retweeted
Hematology Post Doc Research Fellow Job Opening @washumedicine St. Louis, MO
Info/Apply HERE: wustl.wd1.myworkdayjobs.com/…
Lab Info: thekanglab.org/
#InsideTheMatch
Waled Bahaj, MD retweeted
Congratulations @OpsBug @abdulmoiz82! Differential prognostic impact of NPM1-MT AML underscores the need for age-adapted risk stratification models @MDPIOpenAccess @jeffMDMBA @NanjaSushmitha @JulieBoerner2 @CarmeloGurnari @Bahaj_MD @tariqkewan @VisconteValeria
Waled Bahaj, MD retweeted
Original Article: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma (AQUILA) nej.md/3Zh3pOJ
#ASH24 | @ASH_hematology
Waled Bahaj, MD retweeted
NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph+ #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1
@NicholasShortMD of @MDAndersonNews #Leukemia
doi.org/10.1080/17474086.202…
#leusm
Waled Bahaj, MD retweeted
Sensational multicenter collaborative work presented by Yale fellow @tariqkewan on the clinical implications of tp53 mutation in patients with MDS!! @YaleCancer @Dr_AmerZeidan #ASH23
Waled Bahaj, MD retweeted
Honored to be co-senior author on Imetelstat for lower-risk MDS The Lancet manuscript thelancet.com/journals/lance… collaborative effort w great colleagues , hope next rx to approve for MDS. @Dr_AmerZeidan @UwePlatzbecker @Santin13Valeria @MikkaelSekeres @madanatyazan @madicamp
Waled Bahaj, MD retweeted
Proud Moment 🎊🎊 Honored to take part of @TheLancet publication along with brilliant #MDS gurus around the world 🌎 looking forward to seeing #Imetelstat become an option for patients with LR-MDS! @utswcancer @UTSWNews @UTSWInternalMed
Honored to be co-senior author on Imetelstat for lower-risk MDS The Lancet manuscript thelancet.com/journals/lance… collaborative effort w great colleagues , hope next rx to approve for MDS. @Dr_AmerZeidan @UwePlatzbecker @Santin13Valeria @MikkaelSekeres @madanatyazan @madicamp
Waled Bahaj, MD retweeted
I’m at the point where I will rather quit than do @ABIMcert Longitudinal Knowledge Assessment (LKA) and try to keep ABIM certification active.
It’s interfering with patient care and research for me. And I’m getting the myeloma questions wrong. Useless.
@Rfonsi1 #MedTwitter
nejm.org/doi/full/10.1056/NE…
Another great study: Perioperative Nivolumab shows better pCR and better OS
Waled Bahaj, MD retweeted
Presented at #ASCO23: In the KEYNOTE-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. Two-year event-free survival was 62.4% with pembrolizumab & 40.6% with placebo.
Waled Bahaj, MD retweeted
Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM nejm.org/doi/full/10.1056/NE…
Waled Bahaj, MD retweeted
The CAR T-cell therapy ide-cel is approved in the U.S. for relapsed or refractory multiple myeloma after the receipt of at least four previous lines of therapy. Its efficacy earlier in treatment is unknown. Research findings are summarized in a video. nej.md/40yOq2w























